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Enzymology of Protein Folding, Halle, GermanyABSTRACT Liver fatty acid binding protein (L-FABP), a cytosolic protein most abundant in liver, is associated with intracellular
transport of fatty acids, nuclear signaling, and regulation of intracellular lipolysis. Among the members of the intracellular lipid
binding protein family, L-FABP is of particular interest as it can i), bind two fatty acid molecules simultaneously and ii), accom-
modate a variety of bulkier physiological ligands such as bilirubin and fatty acyl CoA. To better understand the promiscuous
binding and transport properties of L-FABP, we investigated structure and dynamics of human L-FABP with and without bound
ligands by means of heteronuclear NMR. The overall conformation of human L-FABP shows the typical b-clam motif. Binding of
two oleic acid (OA) molecules does not alter the protein conformation substantially, but perturbs the chemical shift of certain
backbone and side-chain protons that are involved in OA binding according to the structure of the human L-FABP/OA complex.
Comparison of the human apo and holo L-FABP structures revealed no evidence for an ‘‘open-cap’’ conformation or a ‘‘swivel-
back’’ mechanism of the K90 side chain upon ligand binding, as proposed for rat L-FABP. Instead, we postulate that the lipid
binding process in L-FABP is associated with backbone dynamics.INTRODUCTIONFatty acid binding proteins (FABPs) are a group of abundant
cytosolic proteins that carry long chain fatty acids (LCFAs)
and facilitate the LCFA transport through the aqueous envi-
ronment inside numerous types of cells. As a supplement to
fatty acid (FA) free diffusion, transport in such a protein-
bound form could traffic FA molecules to specific cellular
locations for utilization and function, and thus facilitate
nuclear signaling and regulation of the intracellular lipid
metabolism (1).
FABPs usually exhibit a tissue-specific expression
pattern, and many different homologs have been found in
various tissues of vertebrates (2). These FABPs, together
with the ileal bile acid binding protein (I-BABP), cellular
retinoic acid binding proteins (CRABPs), and cellular
retinol binding proteins (CRBPs), comprise the intracellular
lipid binding protein (iLBP) superfamily and are believed to
be duplicated from a single ancestral gene (3,4). Although
iLBPs, which all have a molecular mass of 14–15 kDa,
exhibit a high degree of sequence homology and share
a conserved tertiary structure, they show some functionalSubmitted October 26, 2011, and accepted for publication April 10, 2012.
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0006-3495/12/06/2585/10 $2.00divergence relating to their particular lipid-binding prefer-
ences. The FA binding specificities and affinities of FABPs
for example are varied. Unlike most FABPs, which gener-
ally bind a single LCFA molecule reversibly (epidermal
FABP, i.e., E-FABP, can alternatively bind an eicosanoid),
liver FABP (L-FABP) is capable of binding two LCFA
molecules simultaneously as well as a large spectrum of
hydrophobic ligands such as bilirubin (5), monoglycerides
(6), bile acids (7), and fatty acyl CoA (8). This unique FA
binding stoichiometry and broad ligand binding spectrum
of L-FABP make this protein especially interesting for
detailed investigations that are furthermore vital for
a more precise understanding of the entire iLBP family.
The crystal structure of rat L-FABP revealed a signifi-
cantly larger binding cavity volume (440 A˚3) compared to
those of other iLBPs (210–330 A˚3) (9). An important struc-
tural property of this larger cavity is the presence of seven
key residues (S39, N61, T93, S100, T102, N111, and
S124) with smaller side chains than in the other iLBP family
members. This feature was hypothesized to partly explain
the unique functional properties of L-FABP (9).
We have postulated in the past that the diversity of FABPs
and their functional differences might be explained by
subtle structural differences that in some cases give rise
to very different protein dynamics (10,11). Studies with
I-BABP have indicated that a less rigid structure permits
the protein to more efficiently allow the entry and exit of
larger ligands (11). Evidence for a similar dynamic behavior
has been documented also for several other iLBPs, including
E-FABP (12) and CRBP-II (13).
Here, we extend the NMR-based studies of iLBPs, previ-
ously applied in our lab to I-BABP as well as intestinal
FABP (I-FABP) and FABP from the flight muscle ofdoi: 10.1016/j.bpj.2012.04.039
2586 Cai et al.Locusta migratoria (Lm-FABP) (14–17), to human L-FABP
both in the presence (holo form) and absence (apo form) of
ligands. The aim of this investigation is to better understand
the binding properties of L-FABP and their functional rele-
vance. The human apo and holo L-FABP structure as well as
the oleic acid (OA) conformations in the first reported
human L-FABP/OA complex structure will be compared
with other L-FABP structures from the RCSB database.
Moreover, 15N relaxation data provide evidence that back-
bone flexibility in the portal region plays a critical role in
ligand binding to human L-FABP. On the basis of these
new insights on L-FABP structure and dynamics, the ligand
binding process will be reassessed.MATERIALS AND METHODS
Protein expression and purification
The cDNA of human L-FABP was ligated into the pMON expression vector
and transformed into Escherichia coli MG1655 cells. Protein expression
was induced by the addition of 50 mg/L nalidixic acid, when the trans-
formed cells grown in LBmedium reached an OD600 of ~0.8 at 37
C. About
4 h after induction, the cells were harvested by centrifugation. For isotope
labeling, M9 medium with 15NH4Cl [
15N, 99%] (Cambridge Isotope Labo-
ratories, Andover, MA) was used as the sole nitrogen source (18).
To purify the protein, cells with expressed L-FABP were suspended in
cell lysis buffer and sonicated over ice. After removing cell debris by centri-
fugation, DNA precipitation was performed with 1% (w/v) protamine
sulfate. Subsequent acidic precipitation at pH 5.5, achieved by adding drop-
wise 2 M sodium acetate (pH 5.0), helped to remove the endogenous lipids
of E. coli as well as unwanted proteins from the mix. The protein sample
was chromatographed on a HiTrap Q HP column (GE Healthcare, Piscat-
away, NJ) equilibrated with 10 mM Tris buffer (pH 8.0), followed by
a gel filtration run with a HiLoad 16/60 Superdex 75pg column (GE Health-
care) to remove higher molecular weight impurities. A final chromatog-
raphy step using a Mono Q 5/50 GL ion exchange column (GE
Healthcare) was helpful for refining the protein purity.
The protein identity was verified by MALDI-TOF mass spectrometry.
The protein concentration was determined using the Modified Lowry Assay
kit from Thermo Scientific (Waltham, MA) (19). Fatty acid analysis by gas-
liquid chromatography was performed to check for endogenous FA bound
to the purified protein (20). The FA content in the apo L-FABP samples was
below 10%.Sample preparation
Non- and 15N-labeled apo and holo L-FABP samples of 2–3 mM concentra-
tion were prepared in 20 mM KH2PO4 buffer (150 mM NaCl, 0.05% NaN3,
pH 6.0). To obtain holo L-FABP samples, the protein was relipidated by
adding 6-molar excess of potassium oleate to ensure that both binding sites
are occupied by FA.NMR data collection and processing
NMR measurements were performed at 25C on a Bruker DMX 500 MHz
spectrometer with a 5 mm TXI probe or a Bruker AVANCE 800 MHz spec-
trometer with a 5 mm TCI cryoprobe. All chemical shift values were refer-
enced to external sodium 2,2-dimethyl-2-silapentane-5-sulfonate (21).
Two-dimensional (2D) TOCSY, NOESY, and HSQC spectra as well as
three-dimensional (3D) 15N-edited TOCSY-HSQC and NOESY-HSQC
spectra were recorded using standard pulse sequences. The TOCSYBiophysical Journal 102(11) 2585–2594spinlock time was set to 80 ms, or 6 ms to obtain COSY-type information.
Mixing times of the NOESY experiments were set to 140–150 ms.
The NMR data were processed with XWINNMR 2.6 (DMX 500) or
TopSpin 1.3 (AVANCE 800). Peak picking and spectra analysis were
carried out using NMRViewJ (One Moon Scientific, Newark, NJ) (22).NMR assignments and structure calculations
Sequential resonance assignments were obtained by applying the strategy
established by Wu¨thrich (23). Side-chain resonances were assigned with
the help of COSY-type spectra.
Distance restraints generated from NOEs between spin pairs with
distances smaller than 5 A˚ were used for structure calculations carried
out by the CYANA 2.1 program (L.A. Systems, Tokyo, Japan) (24,25).
CYANA enables an automatic NOE assignment within seven cycles of
structure calculation. Appropriate calibration constants were applied so
that the minimum, average, and maximum distance restraints were cali-
brated to 1.8, 4.0–4.5, and 6.0 A˚, respectively. Small NOEs derived from
spin diffusion were subsequently eliminated. Seven cycles of NOE assign-
ments and simulated annealing were performed, resulting in an ensemble of
20 conformers and assignments for the NOE peak list in the final cycle.
Based on the structural statistics, the NOE assignments were then modified
manually to further refine the structure. Stereospecific assignments for pro-
chiral groups were made with GLOMSA (26). A final manual calculation
was subsequently performed with the stereospecific assignments and upper
distance limits introduced in the seventh cycle of automatic CYANA calcu-
lation. The 20 best CYANA conformers were finally subjected to restrained
energy minimization calculations using a distance-dependent dielectric
model to mimic the presence of water, as previously described (16). The
quality of the final structures was analyzed by PROCHECK-NMR (Roman
Laskowski, Cambridge, UK) (27). The figures of the structures were gener-
ated with PyMOL (Schro¨dinger LLC, Portland, OR) and MolMol (Kurt
Wu¨thrich, Zu¨rich, Switzerland).
Intermolecular distance restraints between OA and the protein were ob-
tained from a 3D 13C-edited NOESY-HSQC spectrum collected at 10C
using an L-FABP sample complexed with uniformly 13C-labeled OA (Cam-
bridge Isotope Laboratories, Andover, MA). The L-FABP/OA complex
structure was derived from molecular docking and subsequent molecular
dynamics calculations based on intra- and intermolecular distance restraints,
as described elsewhere (17).15N relaxation measurements and model-free
analysis
All 15N relaxation measurements were performed at 500 MHz and 25C.
Sensitivity-enhanced 15N longitudinal (T1) relaxation data were collected
for both apo and holo L-FABP with T1 delays of 14, 30, 46, 78, 110,
158, 222, 302, 398, 510, and 638 ms. 15N transverse (T2) relaxation
measurements were acquired with T2 delays of 17.6, 35.2, 70.4, 88.0,
105.6, 140.8, 158.4, 193.6, and 211.2 ms. R1 and R2 values were calculated
for each backbone amide group with the NMRViewJ program (22) by fitting
to a two-parameter single-exponential decay using the observed peak inten-
sities. Steady-state heteronuclear 1H-15N NOEs were measured in an inter-
leaved way and calculated for each backbone amide group as the ratio of
peak intensities with and without proton saturation (28).
To obtain the generalized order parameter (S2) values for each backbone
N-H vector, model-free analysis was carried out using the DYNAMICS 3.0
program (29,30) by fitting the relaxation parameters R1, R2, and heteronu-
clear NOE to five different models consisting of up to three microdynamic
parameters (i.e., combinations of S2, te, Rex, and Sf
2). Although a small
anisotropy was determined for L-FABP using the r2r1_diffusion program
(31), application of an anisotropic model resulted in fewer residues that
could be fitted. Therefore, analogous to other dynamics studies, which
had previously demonstrated not much of a difference for the moderately
The Human L-FABP/OA Complex 2587asymmetric iLBPs (10,12,32–34), an isotropic rather than an axially
symmetric diffusion tensor was chosen for model-free analysis. The initial
overall correlation time tc was estimated at 6.7 ns for apo L-FABP by using
the R2/R1 ratios of 68 residues. Residues whose R2/R1 ratios exceeded one
standard deviation from the mean value were excluded from this estimation,
assuming that a high R2 value might be due to conformational exchange
(28,35). During the model-free analysis, tc was optimized to 6.20 and
6.15 ns for apo and holo L-FABP, respectively.RESULTS
iLBPs are highly amenable to NMR studies because of their
relatively small molecular weight, mostly b-sheet structure,
and high aqueous solubility as monomers. Here, we applied
standard 2D and 3D NMR methods as in our previous
studies of other FABP family members (14,15,17) to obtain
resonance assignments of human L-FABP that can be used
for structure calculations.FIGURE 1 Solution structures of human apo and holo L-FABP. (A) The
top 20 conformers of human apo (blue) and holo (red) L-FABP are super-
posed. (B) Ribbon diagram of the lowest-energy human apo L-FABP
conformer. The 10 antiparallel b-strands are labeled A through J, and theResonance assignments
Homo- and heteronuclear TOCSYand NOESY spectra were
collected for both human apo and holo L-FABP to identify
1H spin systems and to determine their sequential connectiv-
ities. In total, 124 of 127 backbone amide signals were
found in the HSQC spectra (Fig. S1 in the Supporting Mate-
rial) for both lipidation states. The apo L-FABP spectra re-
vealed no additional signals relating to any FA-bound form.
The lack of resonances belonging to M1 could be explained
by mass spectrometric analysis, which indicated a posttrans-
lational cleavage of the initial methionine. The 1H assign-
ments of both the sole proline residue (P25), which lacks
a backbone amide proton, and the N-terminal serine residue
(S2), whose amide protons could not be observed due to fast
solvent exchange, were obtained from the homonuclear 2D
spectra. The complete 1H and 15N resonance assignments
thus obtained for human apo and holo L-FABP have been
deposited in the BMRB database under entry numbers
17302 and 17303, respectively.two short a-helices are designated as aI and aII.Solution structure of human apo L-FABP
The tertiary structure of human apo L-FABP was obtained
from torsion angle dynamics calculations using 2117 NOE-
derived distance restraints. The backbone traces of the top
20 apo L-FABP conformers (structural statistics in Table
S2) after the final CYANAcalculation and subsequent energy
minimization are superposed in Fig. 1A, featuring a pairwise
root mean-square deviation (RMSD) of 0.94 5 0.12 A˚
between the heavy backbone atoms of the top 20 conformers.
The structure coordinates have been deposited at the RCSB
database under the ID code 2L67.
Fig. 1 B shows a ribbon drawing that represents the
human apo L-FABP structure with the least distance
restraint violations (i.e., the lowest target function). It
reveals the typical iLBP fold, with 10 antiparallel b-strands(A through J) arranged in two almost orthogonal b-sheets
that form a b-clam structure closed on one side by two short
a-helices. A continuous hydrogen-bond network is formed
throughout the b-sheet structure except for a gap between
b-strands D and E. Few interstrand backbone-to-backbone
NOE connectivities (e.g., N61 Ha to E72 HN) were
observed in the gap region, but several long-range NOEs
have been detected between side-chain protons of b-strands
D and E (e.g., between N61 and L71).Solution structure of human holo L-FABP
The same strategy employed for human apo L-FABP was
applied to also determine the structure of the human holoBiophysical Journal 102(11) 2585–2594
2588 Cai et al.form, except that the protein sample was prepared as
a complex with two OA molecules. To ensure that both
binding sites are occupied, excess OA was added to the
protein sample.
The backbone traces of the top 20 holo L-FABP
conformers (structural statistics in Table S2) after the final
CYANA calculation and subsequent energy minimization
were superposed (Fig. 1 A), featuring a pairwise backbone
RMSD of 0.99 5 0.16 A˚. The structure coordinates have
been deposited at theRCSBdatabase under the ID code 2L68.
The secondary structure elements of human holo L-FABP
are almost the same as in the apo form. In holo L-FABP,
a-helix II as well as b-strands C, D, E, and J are slightly
longer, whereas b-strands H and I are slightly shorter
compared to the apo protein (Table 1). Interestingly, a-helix
II and b-strands C through E all relate to the portal region,
which is composed of a-helix II, b-turn CD (bCD), and
b-turn EF (bEF). These structural differences between
human apo and holo L-FABP thus suggest that this portal
region might be stabilized by ligand binding, as previously
observed also for other iLBPs (4,13). Moreover, superposi-
tion of the apo and holo conformers (Fig. 1 A), resulting in
a pairwise backbone RMSD of 1.14 5 0.24 A˚, which is
similar to the pairwise backbone RMSD values of the apo
(0.94 A˚) and holo (0.99 A˚) L-FABP structures themselves,
reveals that the only region that shows a significant though
minor conformational deviation upon ligand binding is
a-helix II; otherwise, the overall protein conformation
remains essentially the same.FIGURE 2 Conformational variabilities of the human apo (A) and holo
(B) L-FABP structures. Conformational variabilities are demonstrated by
worm representations of the top 20 conformers. The thickness of the ribbon
is proportional to the square of the average backbone RMSD per residue.Conformational variabilities in human L-FABP
The solution structures of human apo and holo L-FABP
furthermore indicate a possible influence of ligand binding
on the protein dynamics. Superposition of the top 20
conformers reveals different conformational variabilities
in certain regions of the protein structures. In worm plot
representations of the structures (Fig. 2), the thickness of
the ribbon is proportional to the square of the average
RMSD per residue over all heavy backbone atoms (i.e., N,
C, Ca, and O).
In the case of human apo L-FABP (Fig. 2 A), the b-strands
and a-helix I are well defined, with small backbone RMSD
values compared to a-helix II or the turn regions (Table S2).
The turn bCD for example shows the highest backbone
RMSD. The average backbone RMSD of the b-strands is
0.65 A˚, well below the overall backbone RMSD value of
0.94 A˚. The average backbone RMSD of a-helix II
(1.40 A˚) is significantly higher than that of a-helix I
(0.58 A˚), suggesting a more flexible structure of a-helix
II. The portal region, formed by a-helix II as well as the
turns bCD and bEF, thus displays a higher conformational
variability (1.51 A˚) in human apo L-FABP as opposed to
the nonportal regions (0.74 A˚), suggesting a likely role as
entry and exit region for ligands. Certainly, it must beBiophysical Journal 102(11) 2585–2594pointed out that this large backbone RMSD of the portal
region could be also due, at least in part, to a lack of a suffi-
cient number of NOE connectivities that restrain the confor-
mational space. In this particular case, however, with 85
medium- and 71 long-range distance restraints for the portal
residues, including 47 long-range NOEs between different
secondary structure elements, the amount of structural infor-
mation in the portal region should be sufficient.
The overall backbone RMSD of human holo L-FABP is
slightly higher than for the apo form (Table S2). The same
is true for the average backbone RMSD values of the
b-strands and a-helix I. This might be due to the lower
number of interresidual distance restraints (1937) available
for the structure calculation of the holo protein. However,
in addition to the previously mentioned positional change,
The Human L-FABP/OA Complex 2589a drastic decrease in the backbone RMSD value of a-helix II
is observed in the holo protein (0.83 A˚) as opposed to the
apo form (1.40 A˚), while the average backbone RMSD of
the portal region interestingly remains the same, indicating
a slightly displaced yet more stabilized a-helix II upon OA
binding. The conformational variabilities of human holo L-
FABP are also indicated in a worm plot (Fig. 2 B).FIGURE 3 Comparison of the generalized order parameter (S2) values of
human apo (A) and holo (B) L-FABP plotted against the protein sequence.
The secondary structure elements are indicated by filled (a-helix) or empty
(b-strand) boxes on top. The S2 ¼ 0.60 level is indicated by a dashed line.Backbone dynamics of human L-FABP
The differences in backbone flexibility indicated by the
structural variabilities in the human L-FABP solution struc-
tures were further investigated by 15N relaxation measure-
ments to obtain a more precise characterization of the
L-FABP backbone dynamics. The relaxation rates R1 and
R2 as well as the heteronuclear NOE were determined for
each backbone N-H vector (Fig. S3) and applied to
a model-free analysis to generate generalized order param-
eter (S2) values that represent internal motions on the ps-
to-ns timescale (Table S4).
In the case of apo L-FABP, the S2 values thus obtained
(Fig. 3 A) showed an average value of 0.78 5 0.14.
However, the nonterminal residues L24, E26, G32, G37,
Q43, I59, E72, G76, K78, K80, E86, G87, and L104 dis-
played considerably smaller order parameter values (S2 <
0.60). The majority of those residues are located in structure
elements defining the portal and gap of L-FABP, as shown
also in an analogous study (36), suggesting a higher back-
bone mobility in these regions of the protein. Moreover,
a comparison of different structure elements (Table S5)
shows that the average order parameters are particularly
low in a-helix II, b-strand F, the turns bEF and bFG, as
well as the linkers aI-aII and aII-bB of apo L-FABP, i.e.,
mainly the portal and gap regions. Hence, there is good
agreement between the relaxation data and the conforma-
tional variabilities in the solution structure, as a-helix II is
overall much more flexible (average S2¼ 0.71) than a-helix
I (average S2 ¼ 0.81), and also the portal region reveals
a higher mobility (average S2 ¼ 0.71) compared to the non-
portal part of the protein (average S2 ¼ 0.79).
In the case of holo L-FABP, the average order parameter
value increased to 0.83 5 0.13 (Fig. 3 B). Moreover, the
nonterminal residues with order parameters below 0.60 in
apo L-FABP generally featured significantly higher order
parameters in the holo form, indicating a stabilizing effect
on the backbone mobility due to FA binding. In fact,
a marked increase in the average S2 values was observed
in a-helix II, b-strand D, turn bEF, and turn bFG (Table
S5). In particular, the average order parameter of a-helix
II increases from below average (S2 ¼ 0.71) in apo
L-FABP to above average (S2¼ 0.87) in the holo form, indi-
cating that the previously observed conformational variabil-
ities indeed reflect differences in backbone dynamics
between apo and holo L-FABP. However, although a stabi-
lizing effect due to FA binding is observed throughout theentire portal region, as indicated already by the minor differ-
ences in secondary structure between apo and holo form
(Table 1), the order parameter values obtained for holo
L-FABP demonstrate an unusually high backbone flexibility
in the portal region compared to other iLBPs such as
H-FABP, E-FABP, and CRBP-I (10,12,34).Ligand conformations in the human L-FABP/OA
complex
Based on 31 additional intermolecular distance restraints
(Table S6), which were derived from NOE connectivities
between human L-FABP and its 13C-labeled ligands, the
structure of the human L-FABP/OA complex (Fig. 4 A)
was obtained by docking two OA molecules into the holo
L-FABP solution structure. The carboxylate group of the
innermost OA molecule, which is bound in a U-shaped
conformation along the bottom of the protein cavity, shows
a hydrogen bond to the guanidinium group of R122, as isBiophysical Journal 102(11) 2585–2594
TABLE 1 Secondary structure elements of human apo and
holo L-FABP
Residues
Apo Holo
a-Helix elements*
aI 15–22 15–22
aII 26–32y 26–34
b-Strand elements*
bA 5–13 5–13
bB 38–44 38–44
bC 47–53 47–54
bD 58–64 57–64
bE 68–71 68–72
bF 79–82, 84–86 79–82, 84–86
bG 90–94 90–94
bH 99–105 99–103
bI 108–114 110–115
bJ 119–126 118–126
*Defined according to PROCHECK-NMR (27).
yDeviations between apo and holo L-FABP are indicated in italic font.
2590 Cai et al.typical for FABPs. The second OA molecule displays
a stretched conformation with its methyl end located near
the center of the first OA and its carboxylate group
protruding out of the cavity at the portal. This structural
arrangement inside the human L-FABP cavity differs from
the rat L-FABP solution structure (PDB ID: 2JU8), where
the methyl ends of both OA molecules are interchanged in
their relative positions, but agrees quite well with the crystal
structure of rat L-FABP (PDB ID: 1LFO). The structure
coordinates of the L-FABP/OA complex have been depos-
ited at the RCSB database under the ID code 2LKK.
For a well-folded protein like human L-FABP, changes in
the local chemical environment caused by ligand binding
can be clearly observed in the NMR spectra as chemical
shift perturbation (CSP) effects. These CSP effects become
evident for example when 2D 1H-15N HSQC spectra of apo
and holo L-FABP (Fig. S1) are overlayed, and can be
analyzed quantitatively by comparing the chemical shift
differences of the backbone protons (i.e., HN and Ha) or
the side-chain protons. In the case of the side-chain protons,
the NεH resonance of R122 shows a remarkable downfield
shift of 2.79 ppm to d ¼ 10.29 ppm compared to the apo
form (d ¼ 7.50 ppm). This is a result of the electrostatic
interaction with the carboxyl group of the inner OA mole-
cule. Moreover, one of the CbH resonances belonging to
N61, whose side chain also is located inside the protein
cavity, featured an upfield shift by 1.09 ppm upon OA
binding. Other side chains that showed significant chemical
shift changes (CSP> 0.30 ppm) include M19, I41, F48, I59,
F63, I98, and N111, all of which line the protein cavity. The
largest changes in backbone proton chemical shift were
found for residues G32, G37, V38, F50, N61, and M74
(CSP R 0.50 ppm), but significant chemical shift changes
were identified also for the backbone protons of S39, V42,
I52, T53, A54, S56, K57, Q60, F63, and E72 (CSP >Biophysical Journal 102(11) 2585–25940.30 ppm). These CSP effects observed upon ligand binding
are in agreement with the structure of the human L-FABP/
OA complex (Fig. 4 B).
CSP effects reflect local changes in the chemical environ-
ment that could be interpreted either as an intermolecular
interaction between the protein and its ligand(s) or as
a conformational change triggered by ligand binding.
Most CSP effects observed in human L-FABP are in fact
due to direct contacts between L-FABP and the two OA
molecules, such as in the case of E72 and M74, which
show vdW interactions with the methyl end of the inner
FA, or G32 and S56, which constrain the carboxylate end
of the outer FA between them. In fact, a salt bridge to the
ε-amino group of K31 (a-helix II) and a hydrogen bond to
the S56 hydroxyl group (turn bCD), as previously observed
also in the x-ray structure of rat holo L-FABP (9), apparently
affix the carboxylate group of the outer OA molecule to the
protein, thus explaining the previously mentioned slight
positional deviation and reduced mobility of a-helix II.
Moreover, this scenario also accounts for the large CSP
effect and increased order parameter of G37, which is
located in the aII-bB linker and has no direct contact to
either FA ligand. Hence, it seems that the positional change
of a-helix II is apparently enabled by the flexibility of for
example G37 in this linker region, which is replaced in
most other iLBPs by a much more rigid proline residue.DISCUSSION
As the primary FABP expressed in liver, L-FABP is very
unique in its ability to bind various bulky endogenous
ligands and in its capacity for binding two FA molecules
at the same time. Although it was the first FABP discovered
(5,37), the molecular mechanisms behind the promiscuous
L-FABP binding properties still remain to be understood.
Before we initiated this project, the only L-FABP structure
available was the crystal structure of rat holo L-FABP com-
plexed with two OA molecules at 2.3 A˚ resolution (PDB ID:
1LFO). In the meantime, two rat and two human L-FABP
structures have been released. Here, we present the first
structure of the human L-FABP/OA complex. Below,
a comparison is made to assess the qualities of the various
L-FABP structures from different species determined by
either NMR or x-ray.
A general limitation of most previously determined
human L-FABP structures is that the lipidation states of
the proteins were not reported. Hence, it is difficult to
compare these structures with other L-FABP apo or holo
forms. FABPs expressed in E. coli cells usually contain
a mixture of endogenous FAs, unless they were subjected
to delipidation protocols during or after the purification. In
the case of the human L-FABP crystal structure (PDB ID:
2F73), a publication describing the protein preparation
procedure does not exist to date. Because no FA molecules
are included in the coordinate file, one could assume that
FIGURE 4 Graphic representations of the human L-FABP/OA complex structure. (A) The bound OA molecules are shown as CPK models (yellow) inside
the binding pocket of human L-FABP (blue cartoon). (B) Highlighted are backbone segments and side chains of human L-FABP that showed significant CSP
effects upon ligand binding. Accordingly, backbone ribbon or side-chain sticks of residues whose proton resonances were affected by OA binding are colored
in orange (CSP R 0.80 ppm), yellow (0.50 ppm % CSP < 0.80 ppm), and green (0.30 ppm % CSP < 0.50 ppm). The two bound OA molecules (stick
representation) are displayed in cyan. (C) Superposition of the OA (black ribbon with yellow ligands) and PA (gray ribbon with blue ligands) complexes
of human L-FABP. (D) The first-bound OA molecule (cyan) contacts the hydrophobic cluster at the bottom of the cavity (orange), whereas its carboxylate
group is bound to R122 and S39 (magenta). The second-bound OA (yellow) interacts with another hydrophobic cluster (blue), whereas K31 and S56 (green)
coordinate its carboxylate group. (Strands bE and bF are not shown as arrows for easier viewing of the protein interior.)
The Human L-FABP/OA Complex 2591this structure represents the apo form. However, the lack of
OA electron density might be also explained by the presence
of a heterogeneous mix of different FA species inside the
protein cavity. The same argument applies to the previously
reported solution structure of human L-FABP (PDB ID:
2PY1), which served as application for a method of rapid
data collection by NMR (38). As the resonance assignments
have not been deposited at the BMRB database, it cannot be
deduced whether this structure represents the apo or holo
form. Moreover, this ‘‘rapid’’ solution structure does not
appear to be particularly well defined, because, for example,
the last two b-strands I and J, which are highly characteristic
and important within the iLBP family, do not even exhibit
the typical b-strand geometry.
iLBP orthologs from different species usually share high
sequence homologies. For human and rat L-FABP, 82.7% of
the amino acid residues are identical; therefore, it can be
assumed that both L-FABP orthologs should have very
similar tertiary structures. A pairwise fit between the human
holo L-FABP (PDB ID: 2L68) with the corresponding rat
holo L-FABP crystal structure (PDB ID: 1LFO) revealsa pairwise backbone RMSD value of 1.33 A˚, suggesting
that the L-FABPs from these two species do share very
similar conformations. On the other hand, the pairwise
backbone RMSD of 2.03 A˚ between the rat holo L-FABP
crystal (PDB ID: 1LFO) and solution structures (PDB ID:
2JU7) indicates that the crystal structure of the rat protein
agrees better with the solution structure of human L-FABP
than with the solution structure of rat L-FABP (39).
In contrast to our human L-FABP solution structures, the
rat L-FABP solution structures used more conformational
restraints such as residual dipolar couplings and showed
considerably lower backbone RMSD values of 0.48 and
0.55 A˚ for apo and holo L-FABP, respectively (39). Align-
ments of the apo and holo L-FABP solution structures
between the human and rat species, however, reveal pair-
wise backbone RMSD values of 3.02 and 2.32 A˚, respec-
tively. The most striking structural difference is that the
rat apo L-FABP features an unusually ‘‘open’’ portal
compared to other FABP structures. Based on this result,
He et al. (39) had proposed a mechanism of ‘‘open’’ and
‘‘close’’ transition between rat apo and holo L-FABP.Biophysical Journal 102(11) 2585–2594
2592 Cai et al.Moreover, the side chain of the positively charged K90,
which is conserved in most iLBPs (e.g., brain, heart, intes-
tinal, and liver FABP as well as CRABP-I, CRABP-II,
CRBP-I, and I-BABP), was found inside the cavity of the
rat apo L-FABP solution structure (PDB ID: 2JU3), whereas
in the corresponding holo form (PDB ID: 2JU7) the K90
side chain lies at the protein surface like in all other known
FABP structures. This unique observation was subsequently
interpreted as a possible driving force for ligand binding,
whereby K90 supposedly attracts the ligand from inside
the binding cavity and then ‘‘swivels back’’ to the surface
upon binding (39).
Neither the ‘‘open-cap’’ conformation nor the ‘‘swivel-
back’’ mechanism of K90 were found in the herein pre-
sented human L-FABP solution structures or in any other
known L-FABP or iLBP structure. Actually, the positive
charge of this fairly conserved lysine residue at the start
of b-strand G, which generally is compensated by the nega-
tive surface charge of the last residue in b-strand F (E86 in
case of L-FABP), shows potential salt-bridge distances in
several of our human L-FABP conformers. Therefore, if
the K90 side chain would in fact swivel from inside the
cavity to the surface upon FA binding, the chemical shift
values of the K90 side-chain protons should display signif-
icant changes due to drastically different chemical environ-
ments. This is not the case, however, for either human or rat
L-FABP. Hence, it is doubtful whether such a mechanism is
realistic.
Instead, our data support the hypothesis that a high degree
of backbone flexibility in the portal region, as indicated by
conformational variabilities and generalized order parame-
ters, allows ligands to enter and exit the protein cavity via
a diffusion-based mechanism as postulated by Hsu et al.
(40). Upon binding of OA, our data clearly demonstrate
a stabilizing effect on the overall structure of human
L-FABP but most conspicuously in the case of a-helix II,
which furthermore shows a minor shift in position between
apo and holo form. Hence, ligand binding apparently
slightly displaces a-helix II and reduces its backbone flexi-
bility in holo L-FABP. Responsible for the increased
mobility of a-helix II compared to other iLBPs apparently
is G37 in the aII-bB linker. The subsequent reduction of
flexibility in a-helix II and the aII-bB linker upon ligand
binding results from binding interactions between the
carboxylate group of the outer OA molecule and L-FABP
residues located in a-helix II (K31) and the turn bCD (S56).
Very recently two new studies on L-FABP have been re-
ported (41,42), both of which clearly demonstrate that the
innermost FA is bound first. An x-ray study of the palmi-
tate (PA) complex of human L-FABP presents structures
of the apo, holo, and an intermediate single-PA bound
form (42). The pairwise backbone RMSD values between
our solution structures and these x-ray structures are 1.30
and 1.20 A˚ for the apo and holo forms, respectively, indi-
cating a very close structural agreement. As in the solutionBiophysical Journal 102(11) 2585–2594structure, a slight displacement of a-helix II (up to 1.5 A˚)
is found also between the x-ray apo and holo forms. The
only major difference in the backbone structures of the
two FA complexes is found in the bEF turn, which is
pushed out further in the OA complex presumably due to
the longer carbon chain of OA (Fig. 4 C), as the M74
methyl group in the PA complex occupies almost the
same position like the methyl group of the inner FA in
the OA complex.
Comparing the ligand conformations in the OA and PA
complexes, the relative positions of both FA molecules are
quite similar (Fig. 4 C). The innermost first-bound FA mole-
cule shows the same curved orientation and relative position
inside the L-FABP cavity, while the outer FA stretches from
the center of the U-shaped inner FA to the opening of the
entrance portal. However, the orientation of the FA bound
to the low-affinity site of L-FABP is reverse in the solution
and x-ray structures. In solution, the NH2 group of N111
shows NOE connectivities to the methyl group of the OA
molecule in the low-affinity binding site (Table S6). The
x-ray structure, on the other hand, shows the carboxylate
group of the second PA molecule buried deep inside the
cavity, supposedly stabilized via interactions with neigh-
boring groups such as N111, R122, and a structured water
molecule, although none of these proposed contacts actually
forms a hydrogen bond to the PA. Moreover, the PA arrange-
ment with the methyl end exposed to the bulk solvent and
the carboxylate group immersed into the binding cavity
without any compensating charge appears energetically
less favorable and contradicts all previous structural assess-
ments of L-FABP/FA complexes (9,39). On closer inspec-
tion of the x-ray data (PDB ID code 3STK), the electron
density in the region of the second binding site seems not
fully convincing, and the fairly high temperature factors
of the second PA molecule and in the portal region
(Fig. S7) are not in line with the generally stabilizing influ-
ence of ligand binding on iLBP structures (4,13). Two
possible explanations for the suboptimal crystallographic
data in this region of the L-FABP/PA complex can be envi-
sioned. Either the low-affinity binding site (in the mM range)
was not fully occupied, thus producing a mixture of the holo
and intermediate forms in the crystal. Or the second PA can
actually bind both ways, resulting in a mixture of two
reverse orientations.
Despite these rather well-defined human L-FABP struc-
tures, the major question, as to how the ligands actually
enter the protein cavity, still remains unanswered, because
the size of the portal in the apo form apparently is too
small for FA molecules to just slide through. In accord
with our observation of increased backbone flexibility in
the portal region of the apo form, the recent x-ray study
also mentions the possibility of a more mobile portal in
the human L-FABP apo form based on temperature factors
(42). In an earlier study on I-BABP, we have already postu-
lated that backbone dynamics modulate function in this
The Human L-FABP/OA Complex 2593family of lipid binding proteins (11). A recent publication
on the two major cellular retinol carriers has confirmed the
influence of protein dynamics on the ligand-binding prop-
erties of iLBPs (13). In the case of human L-FABP the
unusually high backbone dynamics in the portal region
suggests that ligand binding is not a process of major struc-
tural changes such as ‘‘swivel-back mechanism’’ or ‘‘open-
cap conformation’’, but rather a transition of the protein
structure from a slightly more disordered and flexible apo
state of the portal region to a more ordered holo state
with restricted motional freedom. Furthermore, the large
number of Rex terms observed in L-FABP agree with our
previously stated hypothesis that the binding affinity of
iLBPs is additionally influenced by processes that occur
in the b-barrel on the ms-to-ms timescale (10,12). Hence,
the unique binding properties of L-FABP compared to
other iLBPs seem to be related primarily to differences
in the protein dynamics.
In summary, we propose that FA binding to L-FABP is
highly dependent on protein dynamics because the portal
region of apo L-FABP exhibits no gaping hole in the
protein surface large enough for FA entry into the binding
cavity. The pronounced backbone flexibility in the portal
compared to other iLBPs allows considerable movements
of a-helix II, the aII-bB linker as well as turns bCD and
bEF, thus enabling FAs to diffuse into the binding pocket.
The main driving forces for FA molecules to enter the
protein interior are the partially hydrophobic environment
as well as coordination sites for their carboxylate groups
(Fig. 4 D). The first FA thus binds at the bottom of the
cavity above a cluster of hydrophobic side chains belonging
to residues F3, I41, F48, F63, V83, and L91, whereas its
carboxylate group is coordinated by R122 and S39. The
relatively large cavity volume compared to other iLBPs
furthermore permits L-FABP to incorporate a second FA
molecule. The methyl end of the second ligand extends
into the binding cavity, while its carbon chain encounters
among other residues the side chains of a second hydro-
phobic cluster consisting of F15, F18, M19, M113, and
F120. The carboxylate group of the second FA protrudes
from the portal and is coordinated by K31 and S56, thereby
reducing the backbone mobility in the portal region.
However, the still relatively high backbone mobility of
holo L-FABP and the weak binding affinity of the second
FA suggest that this L-FABP/OA complex nevertheless
can easily release bound ligand for delivery to sites of FA
utilization in the cell.SUPPORTING MATERIAL
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